NCT01168882撤回1 期
Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- Agennix
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
The purpose of the study is to determine the safety and tolerability of RGB-286638, a novel, multi-targeted kinase inhibitor, administered to patients with selected, relapsed or refractory hematological malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically/cytologically confirmed diagnosis of:
- •Multiple myeloma (MM)
- •Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
- •Mantle Cell Lymphoma (MCL)
- •Chronic Myelogenous Leukemia (CML)
- •Refractory to/relapsed after and/or intolerant of one or more standard therapies or for which no standard therapy exists.
- •ECOG performance status 0-
- •Adequate bone marrow, cardiovascular, renal and hepatic function
- •Recovery from all adverse events due to prior therapies
- •Contraception
排除标准
- •Prior chemotherapy, monoclonal antibodies, investigational agents, or radiation therapy (involving ≥ 30% of the active bone marrow) within 14 days prior to the first dose (note nitrosoureas and mitomycin are not permitted for at least 42 days before the first dose of RGB-286638).
- •CNS involvement of the hematological malignancy.
- •Active or unstable cardiac disease and/or history of myocardial infarction within 6 months and/or history of clinically significant ventricular arrhythmias.
- •Concomitant therapies that are known to prolong the QT interval and are associated with a risk of Torsades de Pointes (TdP) are not permitted within 7 days before the first dose; however, amiodarone is not permitted within 90 days before the first dose.
- •Patients with uncontrolled and unstable intercurrent illness.
- •Concomitant therapy with inhibitors and/or inducers of CYP450 3A4 within 1 week of the first dose.
- •Bleeding disorder unrelated to hematological malignant disease.
- •HIV or HIV-related malignancy.
- •History of other malignancies except: (i) adequately treated basal or squamous cell carcinoma of the skin; (ii) curatively treated, a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (iii) other curatively treated solid tumor with no evidence of disease for ≥ 2 years.
- •Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
结局指标
主要结局
Maximum Tolerated Dose
时间窗: 28 Days of Cycle 1
次要结局
- Safety and Tolerability of escalating doses of RGB-286638(30 days after the last study drug is given to a subject)
- Objective Tumor Response(At the Time of Final Analysis)
- Pharmacokinetic Properties(At the end of Cycle 1 (28 days))
- Pharmacodynamic properties(At the end of Cycle 1 (28 days))
研究者
相似试验
已完成
1 期
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid TumorsSolid TumorsNCT02610361BeiGene131
已完成
1 期
A Study of CS1003 in Subjects With Advanced Solid TumorsAdvanced CancerNCT03475251CStone Pharmaceuticals108
Unknown
1 期
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsSolid TumorsNCT03634982Revolution Medicines, Inc.133
已完成
1 期
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced TumorsAdvanced CancerNCT02407990BeiGene451
招募中
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerAdvanced Prostate CancerMetastatic Prostate CancerNCT05800665Genentech, Inc.210